35 published articles
As of 2026, oral GLP-1 receptor agonism has Phase 3 RCT evidence supporting its efficacy in obesity. Oral semaglutide 50 mg achieves 15 to 17 percent body-weight reduction, matching the 14·9 percent benchmark of subcutaneous semaglutide 2·4 mg, while orforglipron reached approximately 16 percent in Phase 3 ATTAIN-1. Neither oral agent has matched tirzepatide's approximately 20 percent ceiling.
As of mid-2026, retatrutide's TRIUMPH phase 3 programme has delivered 72-week data confirming weight reductions exceeding 20% at the 12 mg dose — the largest placebo-controlled pharmacological weight-loss signal in a completed RCT. Cardiometabolic endpoints show meaningful improvements in blood pressure, triglycerides, and glycaemic markers. Dose-limiting adverse events are predominantly gastrointestinal and concentrated in the escalation phase.
The FDA's 2026 PCAC actions against BPC-157, TB-500, MOTS-C, GHK-Cu, and Semax reflect regulatory process — not clinical validation or invalidation. All five compounds were evaluated under the 503A Bulks List framework, which requires human safety and efficacy data that none of them possesses. The regulatory outcome maps to an evidence gap, not a clinical verdict.
The 2025 SURMOUNT-5 RCT established that tirzepatide produced approximately 20% mean body-weight reduction versus approximately 14% with semaglutide 2.4 mg over 72 weeks. Comparative cardiometabolic data show superior glycaemic control and lipid remodelling with dual agonism. Cardiovascular event data remain largely observational and directionally mixed in 2026.
BPC-157 has no confirmed membrane receptor as of 2026. A 2026 review in Pharmaceutics by Mateescu and colleagues identifies this receptor-orphan status as the root obstacle to rational analogue design. Without a defined pharmacophore, structure–activity relationship studies cannot guide modifications improving half-life, permeability, or potency. Downstream signalling through Egr-1, FAK–paxillin, and VEGFR2 is characterised, but the upstream receptor remains unknown.
As of 2026, two approved passive immunotherapies — lecanemab and donanemab — demonstrate statistically significant but modest slowing of cognitive decline in early Alzheimer's disease: 27% and 35% respectively on primary clinical scales versus placebo. Effect sizes are real but incremental, confined to amyloid-confirmed early-stage disease, and accompanied by clinically significant ARIA rates that constrain patient selection.
Two 2025–2026 studies — a 32-week RCT in adults with HIV-associated lipohypertrophy and a 24-week pilot in MASLD patients — both detected semaglutide's anti-aging signal primarily through DunedinPACE, a pace-of-aging clock built from longitudinal physiological data. Its structural design makes it uniquely sensitive to short-duration interventions, explaining a ~9% deceleration where cross-sectional age-estimate clocks showed weaker effects.
At its July 23–24, 2026 meeting, the FDA's Pharmacy Compounding Advisory Committee (PCAC) recommended against adding BPC-157 to the 503A Bulks List, citing three biopharmaceutical deficiencies: injectable immunogenicity risk, uncharacterised peptide impurity profiles, and an absence of clinical safety data — gaps catalogued independently in the 2026 Pharmaceutics review by Mateescu et al. (doi:10.3390/pharmaceutics18050625).
A 2026 review in Expert Opinion on Drug Delivery identifies three sequential gastrointestinal barriers as the principal reasons oral semaglutide bioavailability remains approximately 0.4 to 1 percent despite SNAC co-formulation. Acid-mediated unfolding, pepsin proteolysis, and low epithelial permeability each require distinct mechanistic solutions. The review proposes ionic-liquid enteric systems, lipid nanocarriers, and extracellular vesicle platforms as targeted responses.
A 2026 comprehensive review in Drug Design, Development and Therapy (DOI: 10.2147/DDDT.S581491) establishes that semaglutide's cardiorenal benefits operate through five mechanistically distinct pathways: GLP-1 receptor–mediated natriuresis, TLR4/NF-κB and NLRP3 inflammasome suppression, TGF-β fibrosis attenuation, RAAS downregulation, and direct reduction of glomerular hyperfiltration—converging to slow eGFR decline, reduce proteinuria, and improve hard cardiovascular endpoints.
A 2025 narrative review in Current Reviews in Musculoskeletal Medicine (Springer, PMC12446177) concludes that BPC-157 shows robust preclinical regenerative activity across tendon, ligament, muscle, and bone via four distinct molecular pathways, while flagging an unresolved oncogenic risk signal and a complete absence of human clinical trial data as the two central barriers to translation in 2026.
In the SELECT trial — a double-blind RCT of 17,604 non-diabetic adults with obesity or overweight and established cardiovascular disease — semaglutide 2·4 mg once weekly reduced the 3-point MACE composite (cardiovascular death, nonfatal MI, nonfatal stroke) by 20% over a mean 40-month follow-up (HR 0·80; 95% CI 0·72–0·90; p<0·001).